ANXA3 and ovarian carcinoma: Platinum resistance. ANXA3 has been previously described as a potential marker for platinum sensitivity in patients with hepatocellular carcinoma (Pan et al., 2015b), ovarian carcinoma (Yan et al., 2010; Yin et al., 2012), non-small cell lung carcinoma (Wang et al., 2019; Jin et al., 2020) and colorectal carcinoma (Xu et al., 2019).